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Abstract: Chromophobe renal cell carcinoma (chRCC) patients have good prognosis. Only 5%–10%
patients die of metastatic disease after tumorectomy, but tumor progression cannot be predicted
by histopathological parameters alone. chRCC are characterized by losses of many chromosomes,
whereas gene mutations are rare. In this study, we aim at identifying genes indicating chRCC
progression. A bioinformatic approach was used to correlate chromosomal loss and mRNA expression
from 15287 genes from The Cancer Genome Atlas (TCGA) database. All genes in TCGA chromophobe
renal cancer dataset (KICH) for which a significant correlation between chromosomal loss and
mRNA expression was shown, were identified and their associations with outcome was assessed.
Genome-wide DNA copy-number alterations were analyzed by Affymetrix OncoScan® CNV FFPE
Microarrays in a second cohort of Swiss chRCC. In both cohorts, tumors with loss of chromosomes
2, 6, 10, 13, 17 and 21 had signs of tumor progression. There were 4654 genes located on these
chromosomes, and 13 of these genes had reduced mRNA levels, which was associated with poor
outcome in chRCC. Decreased CDKN1A expression at mRNA (p = 0.02) and protein levels (p = 0.02)
were associated with short overall survival and were independent predictors of prognosis (p < 0.01
and <0.05 respectively). CDKN1A expression status is a prognostic biomarker independent of tumor
stage. CDKN1A immunohistochemistry may be used to identify chRCC patients at greater risk of
disease progression.
Keywords: chromophobe renal cell carcinoma; copy number loss; CDKN1A expression; patient
survival; prognosis
1. Introduction
Chromophobe renal cell carcinoma (chRCC) is the third most common histological subtype of RCC
and accounts for approximately 5–7% of RCC [1–3]. Although chRCC patients have better prognoses
than patients with clear cell RCC (ccRCC) or papillary RCC (pRCC) [1–5], about 5–7% of patients
die of metastatic disease [4,6,7]. Therefore, it is of utmost importance to identify prognostic factors,
which can better predict the small patient group with clinical progression after surgical resection.
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The current 2016 World Health Organization (WHO)/International Society of Urological Pathology
(ISUP) grading system and the older Fuhrman grading are not recommended for chRCC [1,8],
although several studies have challenged to develop a histopathological grading system for
chRCC [4,6,7,9–13]. Therefore, chRCCs are currently not graded. Interestingly, only recently, it was
reported that classic chRCC harbors a larger number of chromosomal losses than in the eosinophilic
subtype [14], which is often accompanied by reduced expression of “CYCLOPS” (Copy-number
alterations Yielding Cancer Liabilities Owing to Partial losS)” genes [15].
Recent comprehensive genomic analyses of two chRCC cohorts demonstrated a low exonic somatic
mutation rate in these tumours and identified TP53 (20–32%) and PTEN (6–9%) as the most frequently
mutated genes [16,17]. Casuscelli et al. [7] found increased mutation rates in TP53 (58%) and PTEN
(24%) as well as imbalanced chromosome duplication (≥ 3 chromosomes, 25%) in chRCC patients with
metastatic disease. As the prognostic relevance of these genomic alterations was analyzed separately,
the combinatorial impact of these parameters remained unclear.
In this study, we aimed to identify molecular alterations associated with survival in chRCC.
We analyzed the The Cancer Genome Atlas (TCGA) Kidney Chromophobe (KICH) database [16] and
a Swiss chRCC cohort for chromosomal copy number variation (CNV). Next, we focused on genes,
whose mRNA expression correlated with copy number (CN) loss of chromosomes 2, 6, 10, 13, 17 and 21.
Reduced CDKN1A mRNA and protein expression levels were associated with poor outcome in chRCC.
2. Results
2.1. Chromosomal Loss and Patient Outcome
The loss of one copy of chromosomes 1, 2, 6, 10, 13, 17, 21 and Y occurs in the majority of chRCC
cases. Since losses of chromosomes 1 and Y have been reported in benign oncocytoma [5,16,18,19],
we speculated that only loss of chromosomes 2, 6, 10, 13, 17 and 21 may be associated with outcome in
chRCC patients. The frequencies of loss of these chromosomes were similar in both the TCGA-KICH
and the Swiss cohort. The data are summarized in Table S1. As recently described by our group [14],
CN loss of chromosome 2, 6, 10, 13, 17, and 21 in single analysis is not associated with worse survival
(Figure S1). In contrast, tumors without loss of chromosomes 2, 6, 10, 13, 17 and 21 had 100% survival
in both, the TCGA and Swiss cohort (Figure 1).
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2.2. Identification of Genes Associated with Chromosomal Loss, Decreased Expression and Patient Survival
In search of molecular prognostic markers, we hypothesized that the expression of several
genes located on chromosomes 2, 6, 10, 13, 17 and 21 is influenced by allele loss, which may affect
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prognosis of chRCC. The strategy to identify such genes is presented in Figure 2 and described in
detail in the Materials and Methods section. The 13 candidate genes associated with chromosomal loss,
decreased expression and patient survival in chRCC according to combination of UALCAN [20,21]
and the Human Protein Atlas [22,23] websites are listed in Table 1 and Table S2. Scatter plots
showing the correlation between CNV and mRNA expression levels of the 13 genes according to the
analyzed result acquired from the Broad Institute FIREHOSE [24] website are presented in Figure S2.
mRNA expression levels of the 13 genes in normal tissue and tumors with CN loss and no loss
are illustrated in Figure S3. We performed also Protein–Protein Interaction Networks Functional
Enrichment Analysis using the STRING database to find interactions and pathways shared between
the 13 genes/proteins. The interaction network of the 13 genes is illustrated in Figure S4. We observed
strong interactions between FBXW4 (F-Box and WD Repeat Domain Containing 4), FBXL15 (F-Box
and Leucine Rich Repeat Protein 15) and SOCS3 (Suppressor of cytokine signaling 3) and a weaker
interaction between KLF6 (Krueppel-like factor 6) and CDKN1A. According to the Reactome Pathway
Database FBXW4, FBXL15 and SOCS3 are involved in ubiquitination. Interestingly, KLF6 activates
CDKN1A transcription independent from TP53 and is frequently downregulated in human tumors [25].
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Table 1. Genes with a highly significa t correlation between CNV and mRNA expressio l l, cellular
localization of the r proteins and their function.
Gene Name ChromosomalLocus 1
CNV vs mRNA
Pearson’s Correlation
Coefficient 2
Protein
Expression 3
Protein Function
(GeneCards 4)
CDKN1A 6p21.2 R = 0.4 34, p = .0002 n cleus Cell cyc e regulation
KLF6 10p15.2 R = 0.5474, p < .0001 nucleus Transcriptional activator
FAM160B1 10q25.3 R = 0.7632, p < .0001 cytoplasm unknown
PAOX 10q26.3 0.6088, p < 0.0001 cytoplasm Polyami e oxidase
PWWP2B 10q26.3 R = 0.52, p < .0001 cytoplasm u kn wn
F W4 10q24.32 R = 0. 296, p = .0003 golgi Ubiquiti ation
FBXL15 10q24.32 R = 0.4048, p = 0.0007 cytoplasm Ubiquitination
CASKIN2 17q25.1 R = 0.4364, p = 0.0002 cytoplasm unknown
RTN4RL1 17p13.3 R = 0.4013, p = 0.0008 secreted Brain development
FMNL1 17q21.31 R = 0.3974. p = 0.001 cytoplasm Regulation of cell morphology
RAB37 17q25.1 R = 0.369, p = 0.002 cytoplasm GTPase
SOCS3 17q25.3 R = 0.3611, p = 0.003 cytoplasm Cytokine signaling suppression
C21orf2 21q22.3 R = 0.5435, p < 0.0001 mitochondria Regulation of cell morphology,DNA damage repair
1 Gene, National Center for Biotechnology Information [26], 2 Data from the FIREHOSE, Broad Institute [24], 3 Data
from The Human Protein Atlas [23], 4 GeneCards, The Human Gene Database [27].
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2.3. CDKN1A mRNA and Protein Expression
Among these 13 genes, we focused on CDKN1A whose gene product acts as a cell cycle regulator
being involved in genomic stability [28] for the following reasons: (i) according to the Human
Protein Atlas database for several proteins (PAOX, FBXL15, RAB37, C21orf2) antibodies suitable
for immunohistochemical staining are not available or unspecific; (ii) all proteins but CDKN1A are
either not or only weakly expressed in renal cell carcinoma, which significantly hampers reliable TMA
expression analysis.
In the TCGA-KICH cohort, tumors with high CDKN1A mRNA expression separated by both the
best separation cutoff (p = 0.02, log rank test, Figure 3A and Table S2) and median expression (p = 0.026,
Table S2) had a significantly better prognosis than tumors with low CDKN1A mRNA expression.
Cancers 2020, 12, 4 of 13 
 
CASKIN2 17q25.1 R = 0.4364, p = 0.0002 cytoplasm unknown 
RTN4RL1 17p13.3 R = 0.4013, p = 0.0008 secreted Brain development 
FMNL1 17q21.31 R = 0.3974. p = 0.001 cytoplasm Regulation of cell morphology 
RAB37 17q25.1 R = 0.369, p = 0.002 cytoplasm GTPase 
SOCS3 17q25.3 R = 0.3611, p = 0.003 cytoplasm Cytokine signaling suppression 
C21orf2 21q22.3 R = 0.5435, p < 0.0001 mitochondria 
Regulation of cell morphology, 
DNA damage repair 
1 Gene, National Center for Biotechnology Information [26], 2 Data from the FIREHOSE, Broad 
Institute [24], 3 Data from The Human Protein Atlas [23], 4 GeneCards, The Human Gene Database 
[27]. 
2.3. CDKN1A mRNA and Protein Expression 
Among these 13 genes, we focused on CDKN1A whose gene product acts as a cell cycle regulator 
being involved in genomic stability [28] for the following reasons: (i) according to the Human Protein 
Atlas database for several proteins (PAOX, FBXL15, RAB37, C21orf2) antibodies suitable for 
immu ohistochemical staining are not available or unspecific; (ii) all proteins but CDKN1A are either 
not or only weakly expressed i  renal cell carcinoma, which significantly hampers reliable TMA 
expression anal sis. 
In the TCGA-KICH cohort, tumors with high CDKN1A mRNA expression separated by both the 
best separation cutoff (p = 0.02, log rank test, Figure 3A and Table S2) and median expressi n (p = 
0.026, Table S2) had a significantly better prognosis than tumors with low CDKN1A mRNA 
expression.  
 
(A) 
 
(B) 
Figure 3. Survival analysis of CDKN1A expression in chRCC. (A) CDKN1A mRNA expression and 
overall survival of 64 chRCC patients in the TCGA-KICH dataset from the Human Protein Atlas 
[23]—best cut off was according to FPKM values (Fragments per kilo base per million mapped reads); 
(B) CDKN1A protein expression and overall survival of 57 chRCC patients from the Swiss cohort 
dataset. 
In parallel, we examined CDKN1A protein expression in 57 Swiss chRCCs by 
immunohistochemistry (IHC). All normal renal cells including glomeruli, renal tubules, endothelial 
cells, fibroblasts, inflammatory cells were CDKN1A negative (n = 46), with the exception of a few 
tubules with very weak nuclear CDKN1A staining (Figure 4A). CDKN1A-positive clear cell RCC 
from a previous study served as positive controls (Figure 4B) [29]. A representative image of 
CDKN1A-positive chRCC is shown in Figure 4C and Figure S5. An amount of 30 chRCCs (52.6%) 
Figure 3. Survival analysis of CDKN1A expression in chRCC. (A) CDKN1A mRNA expression
and overall survival of 64 chRCC patients in the TCGA-KICH dataset from the Human Protein
Atlas [23]—best cut off was according to FPKM values (Fragments per kilo base per million mapped
reads); (B) CDKN1A protein expression and overall survival of 57 chRCC patients from the Swiss
cohort dataset.
In parallel, we examined CDKN1A protein expression in 57 Swiss chRCCs by immunohistochemistry
(IHC). All normal renal cells including glomeruli, renal tubules, endothelial cells, fibroblasts,
inflammatory cells were CDKN1A negative (n = 46), with the exception of a few tubules with
very weak nuclear CDKN1A staining (Figure 4A). CDKN1A-positive clear cell RCC from a previous
study served as positive controls (Figure 4B) [29]. A representative image of CDKN1A-positive chRCC
is shown in Figure 4C and Figure S5. An amount of 30 chRCCs (52.6%) were CDKN1A negative,
27 tumors (47.4%) were CDKN1A positive (cut off ≥ 2% tumor cells). There was a significant correlation
between CDKN1A negativity and shorter overall survival (Figure 3B).
Nuclear staining was weak in 19 (70.4%) tumors and 8 (29.6%) showed moderate to strong nuclear
staining. The mean (range) of the H-score (described in Materials and Methods) among CDKN1A
positive tumors was 16.6 (2–110) (Figure S6). Neither staining intensity nor H-score (>20) improved
overall survival rate. Nuclear staining with any intensity and a cutoff of ≥2% positive tumor cells
proved to be the best criteria to differentiate between CDKN1A expression status and patient outcome.
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2.4. CDKN1A Expression, Tumor Stage, Grade and Outcome
Analysis of the TCGA and the Swiss cohort revealed no correlation between CDKN1A expression
(RNA and protein) and tumor stage. Univariate Cox regression analysis showed that both T stage
(p = 0.004) and low CDKN1A mRNA expression (p = 0.001) were significant prognostic factors in the
TCGA-KICH cohort (Table 2). In the Swiss dataset, only the absence of CDKN1A protein expression by
IHC was significantly associated with poor outcome (p < 0.05), whereas advanced pT stage did not
correlate with survival by univariate Cox regression analysis. A recently published two-tiered grading
system was available for the TCGA-KICH cohort [30] and included in our calculations. Univariate Cox
regression analysis demonstrated strong prognostic relevance of this grading system (p < 0.001)
(Table 2).
Table 2. Tumor st ge, histolo ical grading according to necrosis and/or sarcomatoid differentiation,
CDKN1A expression separated by the best separation cutoff from FIREHOSE [24] mRNA data and
overall survival in chromophobe renal cell carcinoma.
Cohort TCGA-KICH Swiss Patients
Variables
Univariate Multivariate2 Univariate Multivariate
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value
Tumor stage
(3–4 vs 1–2) 1
10.22
(2.12–49.29) 0.004
6.442
(1.488–37.214) 0.012
1.447
(0.398–5.264) n.s.
1.266
(0.343–4.678) n.s.
Grade
(High vs Low)
18.03
(4.448–73.05) <0.001
6.087
(1.374–32.266) 0.017 - - - -
CDKN1A
expression
(Low vs High) 2, 3
22.528
(2.862–2904.443) <0.001
12.527
(1.289–1675.059) 0.026
4.812
(1.07–21.64) <0.05
4.741
(1.051–21.390) <0.05
HR, hazard ratio; CI, confidence interval; n.s.: not significant; 1 TCGA-KICH: T stage, Swiss patients: pT stage;
2 Firth correction was used because of quasi-complete separation; there was no event in one of the subgroups;
3 CDKN1A mRNA expression in TCGA-KICH cohort and CDKN1A protein expression in Swiss cohort.
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Multivariate analysis using Cox proportional hazard model revealed T stage (p = 0.012),
grade (p = 0.017) and low CDKN1A mRNA expression (p = 0.026) as significant independent predictors
of poor outcome in the TCGA cohort. In the Swiss dataset, only loss of CDKN1A expression (p < 0.05)
was confirmed as a significant independent predictor of poor outcome (Table 2).
3. Discussion
In this study, we attempted to identify molecular biomarkers with prognostic value in
chRCC. For this purpose, we screened TCGA-KICH data to extract genes located on frequently
deleted chromosomes whose expression is associated with patient outcome. Tumor suppressor
Cyclin-dependent kinase inhibitor 1A (CDKN1A) was among 13 genes which fulfilled these criteria.
We demonstrated that decreased CDKN1A expression at the mRNA and protein levels is an independent
predictor of outcome in two independent chRCC cohorts.
The tumor suppressive role of CDKN1A, also known as p21/Waf1/Cip1, has been widely accepted.
Cellular stressors, such as DNA damage or UV-light, activate tumor suppressor p53, which leads to the
transient expression of CDKN1A. CDKN1A inhibits cyclin-CDK1, -CDK2, and CDK4/6, which regulates
cell cycle progression of G1 and S phases and mediates senescence or apoptosis [28]. Previous studies
emphasize CDKN1A’s important tumor suppressive role by showing that its depletion in cell line
models leads to DNA damage and chromosomal instability [28,31] but also permits carcinogenesis
from chronically damaged kidney epithelial cells [32].
CDKN1A, which resides in 6p21.2, is affected by the frequent loss of one chromosome 6 allele in
chRCC. Analysis of TCGA-KICH data demonstrated that the loss of one CDKN1A allele was closely
linked to lower CDKN1A mRNA expression levels compared to tumors that retained both CDKN1A
alleles. Notably, the overall mRNA expression level in normal renal tissue was higher than in chRCC
with CDKN1A loss and lower than in tumors without CDKN1A loss. This is consistent with the
immunohistochemical CDKN1A protein expression analysis of the Swiss cohort. chRCC cells were
either CDKN1A negative or strongly positive. Nuclei of glomeruli, endothelial cells, and fibroblasts
were negative in the normal kidney. Only some tubular cells had weak CDKN1A expression.
Like CDKN1A on chromosome 6—which is absent in 80% of chRCC—the tumor suppressor genes
PTEN and TP53 are located on chromosomes (chromosome 10 and 17) that are also frequently lost in
chRCC. Whereas PTEN and TP53 are mutated in up to 9% and 32% of chRCC [16,17], respectively,
CDKN1A gene mutations are rare [16,33]. Although immunohistochemical analysis showed no
correlation between CDKN1A, TP53 and PTEN expression in chRCC (TP53 and PTEN positivity was
rare in our chRCC cohort; data not shown), the loss of function of the latter two tumor suppressors
may have significant impact on CDKN1A regulation. One important downstream target of TP53 is
CDKN1A [34]. The downregulation of CDKN1A may thus be caused through loss of functional TP53
in those chRCC in which TP53 is inactivated by two hits, chromosomal loss and mutation. In addition,
it was shown that interaction between PTEN and TP53 stimulates TP53-mediated transcription and
stabilizes TP53 [35–37]. In a minor fraction of chRCC loss of PTEN function may therefore exert similar
negative effects on CDKN1A expression. It is tempting to speculate that a combination of loss of
chromosomes 6, 10, and 17 and molecular two-hit disruption of PTEN and TP53 are the main drivers
for the loss of CDKN1A expression and worse patient outcomes in chRCC.
Importantly, our survival analysis revealed a clear association between reduced CDKN1A mRNA
expression levels and CDKN1A immuno-negativity with worse outcome. Data on the prognostic
relevance of CDKN1A expression are controversial in the literature and seem to be dependent on
cancer type. Increased CDKN1A levels are associated with poor outcome in esophageal, ovarian,
prostate cancers as well as in gliomas [38–43], while loss of CDKN1A expression is associated with
decreased survival in breast, cervical, gastric, and ovarian cancers [44–47]. In some cancers, the loss
of CDKN1A expression upregulates genes that repress CDKN1A transcription, such as MYC [25,48].
Ubiquitin-dependent and -independent proteosomal degradation of CDKN1A may also contribute
to tumorigenesis [25,49]. CDKN1A can also exhibit oncogenic activities in some cancers, which may
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explain the strong correlation of its overexpression with tumor grade, rapid progression, poor prognosis,
and drug resistance [25,28,43,50]. This two-faced nature of CDKN1A seems to be dependent on its
cellular location. Several IHC studies imply that nuclear expression of CDKN1A indicates its
tumor-suppressive role, while its presence in the cytoplasm favors an oncogenic role [25,51–54].
We have observed a significant correlation between CN loss, decreased CDKN1A expression and poor
prognosis, suggesting a tumor suppressive role of CDKN1A in chRCC. This is supported by the strong
CDKN1A positivity seen in tumor cell nuclei of almost half of the analyzed chRCC.
Our proposed data mining strategy demonstrated its usefulness to identify expression patterns of
13 candidate genes with prognostic impact in chRCC. However, the validation of gene expression data
using additional and independent patient cohorts and different technological platforms is of utmost
importance to confirm the robustness of the data. Due to the lack of suitable antibodies and only low
protein expression levels in RCC, we decided to forego an immunohistochemical in situ analysis of 12
of 13 candidates. In contrast to genes and proteins that are highly differentially expressed in cancer,
the validation of low abundance genes as diagnostic and prognostic tools in tumor pathology is a big
challenge. Branched probe-based or enzymatic amplification RNA-ISH methods for the detection and
quantification of transcripts in FFPE tissues [55] may be ideally suited to evaluate cancer biomarker
candidates on the mRNA level. Given the huge amount of survival-related gene expression data in the
TCGA database, systematic and comprehensive gene expression profiling of such candidate genes are
necessary to better understand the complex regulatory network along tumor progression, which may
lead to new therapeutic strategies to treat aggressive chRCC.
From a clinical viewpoint time to progression or tumor-specific rather than overall survival after
tumorectomy are the most important parameter for chRCC [30]. Biomarkers, which predict time to
progression are therefore highly desirable to identify approximately 5%–10% of chRCC at risk for
progression. Additional chRCC cohorts are needed to validate whether the loss of CDKN1A expression
is a reliable molecular marker to detect chRCC patients with at greater risk of disease progression.
4. Materials and Methods
4.1. Data Acquisition and Processing Using the Cancer Genome Atlas Data Portal
Digital whole slide images of TCGA-KICH cases were reviewed using the Cancer Digital Slide
Archive [56]. The corresponding clinical information of TCGA-KICH was obtained from the TCGA Data
Portal [57]. Publically available Level 3 TCGA datasets comprising 66 primary chRCCs (TCGA-KICH)
were downloaded from the Broad Institute TCGA Genome Data Analysis Center via FIREHOSE [24]
including GISTIC copy number (CN) data, Next Generation Sequencing (NGS)-based whole genome
sequencing data and RNA-sequencing data as previously described [14–16,58]. Two patients with
missing or too short follow-up (less than 30 days) were excluded from the Cox regression analysis.
TCGA CNV analysis was performed with Affimetrix SNP 6.0 with cutoff value −0.1 for copy number
loss according to the Broad Institute FIREHOSE website description [24]. Gene expression values were
log2-transformed to plot CDKN1A mRNA expression profiles of normal kidney and tumors with and
without CN loss.
In the TCGA-KICH cohort, the median age at diagnosis was 49.5 years (range 17–86 years).
The median follow-up of the entire cohort was 80.5 months. Nine patients (14.1%) died during
follow-up. Forty-five chRCC were early stage (T1 and T2) and 19 late stage tumors (T3 and T4).
4.2. Strategy for Gene Candidate Selection
In a first step we used the Broad institute FIREHOSE website (“Correlate CopyNumber ys
mRNAseq”) [24] to download all 15,287 available human genes of the whole genome and extracted
4654 with significant positive correlation between gene copy number and mRNA expression (Pearson’s
correlation coefficient R > 0 and p < 0.005).
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1631 of the 4654 genes were located on chromosomes 2, 6, 10, 13, 17 and 21. Since Figure 1
demonstrated chromosomal loss in 84% (79 of 94) chRCC, we hypothesized that by using a two-tiered
separation based on presence or absence of chromosomal losses, the expression patterns of several
genes on chromosomes 2, 6, 10, 13, 17 and 21 would fulfill the UALCAN [20,21] survival curve
separation criteria: patients with high gene expression values > 3rd quartile versus patients with low
gene expression (<3rd quartile). Obtaining survival curves separated by mRNA expression level in
UALCAN [20,21] requires only minimal steps among three websites, UALCAN [20,21], the Human
Protein Atlas [22,23] and FIREHOSE [24]. We entered all 1631 gene symbols in input fields of the
UALCAN [20,21] and extracted the genes of > 3rd quartile high gene expression group with more than
80% overall survival rate. Next, we selected genes, of which the low gene expression was significantly
correlated with poor prognosis (p < 0.05) and high mRNA expression group showed >80% overall
survival rate using the Human Protein Atlas [22,23] (Table S1). Finally, 13 candidate genes were
identified (Table 1).
4.3. Swiss Chromophobe Renal Cell Carcinomas
A total of 57 chRCCs were retrieved from the archives of the Department of Pathology and
Molecular Pathology of the University Hospital Zurich (Zurich, Switzerland). Overall survival data
were obtained from the Zurich Cancer Registry. The study was approved by the Cantonal Ethics
Committee of Zurich (BASEC-No_2019-01959) in accordance with the Swiss Human Research Act and
with the Declaration of Helsinki. All tumors were reviewed by two pathologists (Riuko Ohashi and
Holger Moch) blinded to clinico-pathological information. The tumors were histologically classified
according to the WHO classification [1]. In the Swiss cohort, the median age at diagnosis was 62 years
(range 18–87 years). The median follow-up was 51.0 months and 14 patients (24.6%) died during
follow-up. Tumors were staged according to the TNM staging system [59]. A total of 48 chRCC were
early stage (T1 and T2) and 9 late stage tumors (T3 and T4).
4.4. OncoScan Assay
DNA from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples was obtained by
punching 4 to 6 tissue cylinders (diameter 0.6 mm) from each sample. Punches were taken from
tumor areas displaying >90% cancer cells which were marked previously on Hematoxylin and
Eosin stained slides. DNA extraction from FFPE tissue was done as previously described [14,15,60].
The double-strand DNA (dsDNA) was quantified by the fluorescence-based Qubit dsDNA HS Assay
Kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to manufacturer’s instructions.
Thirty chRCCs had sufficient DNA quality for copy number analysis. Genome-wide DNA copy-number
alterations were analyzed by Affymetrix OncoScan® CNV FFPE Microarrays (Affymetrix, Santa Clara,
CA, USA) as previously described [14,15,61]. The samples were processed by IMGM Laboratories
GmbH (Martinsried, Germany). The data were analyzed by the OncoScan Console (Affymetrix) and
Nexus Express for OncoScan 3 (BioDiscovery, Inc. El Segundo, CA, USA) software using the Affymetrix
TuScan algorithm. The CNV cutoff value was -0.3 for copy number loss in Nexus Express for OncoScan
3 Software (BioDiscovery) default setting.
4.5. Immunohistochemistry
A tissue microarray (TMA) with 57 chRCC was constructed as described [29,62]. TMA sections
(2.5µm) were transferred to glass slides and subjected to immunohistochemistry using Ventana
Benchmark XT automated system (Roche Diagnostics, Rotkreuz, Switzerland). CDKN1A was
immunostained using polyclonal anti-rabbit sc-397 (dilution 1:50; Santa Cruz Biotechnology, Inc.;
Dallas, TX, USA). Immunostained slides were scanned using the NanoZoomer Digital Slide Scanner
(Hamamatsu Photonics K.K., Shizuoka, Japan). Immunohistochemical evaluation was conducted
by two pathologists (R.O. and H.M.) blinded to the clinical data. The criteria for protein expression
analysis were as described in previous TMA studies [15,29]. A tumor was considered CDKN1A positive
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if ≥ 2% of the tumor cells showed unequivocal nuclear expression. A semi-quantitative approach
(H-score) was also performed. The staining percentages (range 0–100%) and the intensity of nuclear
expression of CDKN1A (range 0–3: 0, negative; 1, weak; 2, moderate; and 3, strong) in tumor cells
were evaluated and the H-score was calculated using the formula 1 × (% of 1+ cells) + 2 × (% of 2+
cells) + 3 × (% of 3+ cells) (giving a score that ranged from 0 to 300) [63]
4.6. Statistical Analysis
All statistical analyses were conducted using R, 3.4.1 (R Foundation for Statistical Computing,
Vienna, Austria) and EZR, Version 1.37 (Saitama Medical Center, Jichi Medical University, Saitama,
Japan) [64]. The Fisher’s exact test was used to assess association between two categorical variables.
Overall survival rates were determined according to the Kaplan–Meier method and analyzed for
statistical differences using a log rank test. Univariate and multivariate analyses were performed by
using the Cox-proportional hazard model with Firth’s penalized likelihood [65,66]. Cox regression
analysis was performed using FIREHOSE mRNA expression data [24]. p-values < 0.05 were regarded
as statistically significant.
5. Conclusions
In conclusion, chRCC without loss of chromosomes 2, 6, 10, 13, 17 and 21 have a favorable
prognosis. CDKN1A mRNA and protein expression levels were of prognostic relevance independent
from tumor stage. CDKN1A IHC is easily applicable in routine pathology and will help to stratify
chRCC patients that have a significantly greater risk of disease progression.
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